Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

Summary Background Axitinib (AG-013736) is a potent and selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, which have an important role in pancreatic cancer. The aim of this study was to assess the safety and efficacy of gemcitabine plus axitinib versus gemcitabine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2008-06, Vol.371 (9630), p.2101-2108
Hauptverfasser:	Spano, Jean-Philippe, Prof, Chodkiewicz, Catherine, MD, Maurel, Joan, MD, Wong, Ralph, MD, Wasan, Harpreet, MD, Barone, Carlo, Prof, Létourneau, Richard, MD, Bajetta, Emilio, MD, Pithavala, Yazdi, PhD, Bycott, Paul, DrPh, Trask, Peter, PhD, Liau, Katherine, BS, Ricart, Alejandro D, MD, Kim, Sinil, MD, Rixe, Olivier, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Blood pressure Chemotherapy Clinical medicine Colorectal cancer Data analysis Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug Therapy, Combination Female Humans Imidazoles - administration & dosage Imidazoles - adverse effects Imidazoles - therapeutic use Indazoles - administration & dosage Indazoles - adverse effects Indazoles - therapeutic use Internal Medicine Male Middle Aged Monoclonal antibodies Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Patients Proportional Hazards Models Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Studies Survival Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!